Article(id=1330183520594538700, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1330183519441105099, articleNumber=null, orderNo=null, doi=10.16522/j.cnki.cjph.2023.02.001, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1642608000000, receivedDateStr=2022-01-20, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1795070064923, onlineDateStr=2026-11-19, pubDate=1675958400000, pubDateStr=2023-02-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1795070064923, onlineIssueDateStr=2026-11-19, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1795070064923, creator=13701087609, updateTime=1795070064923, updator=13701087609, issue=Issue{id=1330183519441105099, tenantId=1146029695717560320, journalId=1319690259887390882, year='2023', volume='54', issue='2', pageStart='165', pageEnd='294', issueExtLink='null', onlineDate='null', pubDate='1675958400000', pubDateStr='2023-02-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1795070064649, creator='13701087609', updateTime=1795080429540, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1330226993464979643, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1330183519441105099, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1330226993464979644, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1330183519441105099, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=165, endPage=174, ext={EN=ArticleExt(id=1330183520921694413, articleId=1330183520594538700, tenantId=1146029695717560320, journalId=1319690259887390882, language=EN, title=Research Progress of Androgen Receptor Degraders, columnId=1327671169563603616, journalTitle=Chinese Journal of Pharmaceuticals, columnName=Perspectives, runingTitle=null, highlight=null, articleAbstract=
Due to many factors, such as point mutations in the ligand-binding domain of the androgen receptor(AR) and expression of splice variants, the existing treatment methods for prostate cancer have been successively ineffective. Therefore, new strategies for prostate cancer treatment are urgently needed. In recent years, significant progress has been made in targeted protein degradation technology. For example, AR degraders, which are expected to solve the problem of drug resistance in clinical prostate cancer patients, can block the androgen receptor signaling pathway by promoting AR degradation. This review focuses on the proteolysis targeting chimeras(PROTAC) technology and small molecule degraders targeting AR, and summarizes the research progress in this field from the mechanism of action and representative compounds, respectively. Compared with the inherent druggability defects of PROTAC molecules, small molecule AR degraders have more advantages and are now becoming the leading research direction for the treatment of prostate cancer.
, authors=Ao WANG
1, Yawan WANG
2, Yushe YANG
1, *, authorsList=Ao WANG, Yawan WANG, Yushe YANG, authorCompany=null, correspAuthors=Yushe YANG, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1330183521580200144, articleId=1330183520594538700, tenantId=1146029695717560320, journalId=1319690259887390882, language=CN, title=雄激素受体降解剂的研究进展, columnId=1327671169823650466, journalTitle=中国医药工业杂志, columnName=专论, runingTitle=null, highlight=null, articleAbstract=
由于雄激素受体配体结合域的点突变、表达剪切变异体等诸多因素,使得现有的前列腺癌治疗手段相继无效,因此亟需新的策略用于前列腺癌的治疗。近年来靶向蛋白降解技术取得巨大进展,其中雄激素受体降解剂通过促进雄激素受体的降解来阻断雄激素受体信号通路,有望解决临床前列腺癌患者出现耐药的问题。该综述围绕靶向雄激素受体的蛋白降解靶向嵌合体(PROTAC)技术和小分子降解剂,分别从作用机制和代表性化合物两方面概述了该领域的研究进展。相较于PROTAC分子固有的成药性缺陷,小分子雄激素受体降解剂更具优势,现正成为治疗前列腺癌的主要研究方向。
, authors=王傲
1, 王雅琬
2, 杨玉社
1, *, authorsList=王傲, 王雅琬, 杨玉社, authorCompany=null, correspAuthors=杨玉社, authorNote=
杨玉社,博士,1996年在中国科学院上海药物研究所获得博士学位,现任中国科学院上海药物研究所研究组长、博士生导师和二级研究员。主要从事抗菌药物、抗肿瘤药物、抗凝血药物研发以及药物合成新工艺、新方法的研究,积累了丰富的创新药物研究、开发经验。2009年成功研制出我国第一个具有自主知识产权的氟喹诺酮新药盐酸安妥沙星。近年来主持多项国家新药创制重大专项、自然科学基金、上海市科委新药重点课题,3个1.1类新药转让给企业开发。在J Med Chem、J Org Chem、Bioorg Med Chem Lett、Eur J Med Chem等杂志上发表论文67篇,申请国内、国际专利47项,获授权20余项,其中多项专利转让给国内大型企业实施。在新药产业化方面取得重大成绩,获得国家1.1类新药证书2个,二类新药证书8个。
王傲(1993—),男,博士,从事抗前列腺癌药物研发及合成新工艺的研究。
, correspAuthorsNote=
杨玉社(1963—),男,博士,博士生导师,研究员,从事抗菌药物、抗肿瘤药物、抗凝血药物研发以及药物合成新工艺、新方法的研究。E-mail:
ysyang@simm.ac.cn, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=IxXtp3kkwAon9zCANhpERw==, magXml=iuc5yi/wqVu2+FDOFtfL2g==, pdfUrl=null, pdf=GSIRPYHmEDv8/myVEtvpyw==, pdfFileSize=2144254, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=Xm+2iX74UALDGKzkUFNq7A==, mapNumber=null, fund=null)}, authors=[Author(id=1330183523488608473, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330183523568300251, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, authorId=1330183523488608473, language=EN, stringName=Ao WANG, firstName=Ao, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
1, address=
1.Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330183523631214812, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, authorId=1330183523488608473, language=CN, stringName=王傲, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
1, address=
1.中国科学院上海药物研究所,上海 201203, bio={"content":"
王傲(1993—),男,博士,从事抗前列腺癌药物研发及合成新工艺的研究。
"}, bioImg=null, bioContent=
王傲(1993—),男,博士,从事抗前列腺癌药物研发及合成新工艺的研究。
, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330183521865412817, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, xref=1., ext=[AuthorCompanyExt(id=1330183521873801426, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, companyId=1330183521865412817, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
1.Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203), AuthorCompanyExt(id=1330183521886384339, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, companyId=1330183521865412817, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
1.中国科学院上海药物研究所,上海 201203)])]), Author(id=1330183523719295198, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330183523790598368, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, authorId=1330183523719295198, language=EN, stringName=Yawan WANG, firstName=Yawan, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
2, address=
2.School of Chinese Materia Medic, Nanjing University of Chinese Medicine, Nanjing 210023, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330183523857707233, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, authorId=1330183523719295198, language=CN, stringName=王雅琬, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
2, address=
2.南京中医药大学,新中药学院,江苏 南京 210023, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330183523346002133, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, xref=2., ext=[AuthorCompanyExt(id=1330183523371167958, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, companyId=1330183523346002133, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
2.School of Chinese Materia Medic, Nanjing University of Chinese Medicine, Nanjing 210023), AuthorCompanyExt(id=1330183523408916695, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, companyId=1330183523346002133, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
2.南京中医药大学,新中药学院,江苏 南京 210023)])]), Author(id=1330183523929010403, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=ysyang@simm.ac.cn, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1330183524000313573, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, authorId=1330183523929010403, language=EN, stringName=Yushe YANG, firstName=Yushe, middleName=null, lastName=YANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
1, *, address=
1.Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330183524059033830, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, authorId=1330183523929010403, language=CN, stringName=杨玉社, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
1, *, address=
1.中国科学院上海药物研究所,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330183521865412817, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, xref=1., ext=[AuthorCompanyExt(id=1330183521873801426, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, companyId=1330183521865412817, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
1.Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203), AuthorCompanyExt(id=1330183521886384339, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, companyId=1330183521865412817, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
1.中国科学院上海药物研究所,上海 201203)])])], keywords=[Keyword(id=1330183524151308519, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, language=EN, orderNo=1, keyword=prostate cancer), Keyword(id=1330183524218417384, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, language=EN, orderNo=2, keyword=androgen receptor), Keyword(id=1330183524319080681, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, language=EN, orderNo=3, keyword=proteolysis targeting chimeras(PROTAC)), Keyword(id=1330183524449104106, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, language=EN, orderNo=4, keyword=androgen receptor degrader), Keyword(id=1330183524574933227, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, language=CN, orderNo=1, keyword=前列腺癌), Keyword(id=1330183524730122476, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, language=CN, orderNo=2, keyword=雄激素受体), Keyword(id=1330183524851757293, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, language=CN, orderNo=3, keyword=蛋白降解靶向嵌合体(PROTAC)), Keyword(id=1330183524927254766, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, language=CN, orderNo=4, keyword=雄激素受体降解剂)], refs=[Reference(id=1330183525141164272, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=SIEGEL R L, MILLER K D, GODING SAUER A,
et al. Colorectal cancer statistics, 2020 [J].
CA Cancer J Clin,2020,
70(3): 7-30., articleTitle=null, refAbstract=null), Reference(id=1330183525220856049, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=SIA M, RODRIGUES G, MÉNARD C,
et al. Treatment-related toxicity and symptom-related bother following postoperative radiotherapy for prostate cancer [J].
Can Urol Assoc J, 2010,
4(2): 105-111., articleTitle=null, refAbstract=null), Reference(id=1330183525287964914, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=AGOULNIK I U, WEIGEL N L. Androgen receptor action in hormone-dependent and recurrent prostate cancer [J].
J Cell Biochem, 2006,
99(2): 362-372., articleTitle=null, refAbstract=null), Reference(id=1330183525359268083, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=XU X, DU Q M, MENG Y,
et al. Discovery of pyridine tetrahydroisoquinoline thiohydantoin derivatives with low blood-brain barrier penetration as the androgen receptor antagonists [J].
Eur J Med Chem, 2020,
192: 112196., articleTitle=null, refAbstract=null), Reference(id=1330183525438959860, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=KARANTANOS T, CORN P G, THOMPSON T C. Prostate cancer progression after androgen deprivation therapy:mechanisms of castrate resistance and novel therapeutic approaches [J].
Oncogene, 2013,
32(49): 5501-5511., articleTitle=null, refAbstract=null), Reference(id=1330183525506068725, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=JUNG M E, OUK S, YOO D,
et al. Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer(CRPC) [J].
J Med Chem, 2010,
53(7): 2779-2796., articleTitle=null, refAbstract=null), Reference(id=1330183525573177590, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=CHI K N, AGARWAL N, BJARTELL A,
et al. Apalutamide for metastatic, castration-sensitive prostate cancer [J].
N Engl J Med, 2019,
381(1): 13-24., articleTitle=null, refAbstract=null), Reference(id=1330183525636092151, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=FIZAZI K, ALBIGES L, LORIOT Y,
et al. ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer [J].
Expert Rev Anticancer Ther,2015,
15(9): 1007-1017., articleTitle=null, refAbstract=null), Reference(id=1330183525690618105, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=BRYCE A, RYAN C J. Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor [J].
Clin Pharmacol Ther, 2011,
91(1): 101-108., articleTitle=null, refAbstract=null), Reference(id=1330183525749338362, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=ATTARD G, COOPER C S, DE BONO J S. Steroid hormone receptors in prostate cancer: a hard habit to break?[J].
Cancer Cell, 2009,
16(6): 458-462., articleTitle=null, refAbstract=null), Reference(id=1330183525808058619, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=HU R, LU C X, MOSTAGHEL E A,
et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer [J].
Cancer Res, 2012,
72(14): 3457-3462., articleTitle=null, refAbstract=null), Reference(id=1330183525870973180, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=MOSTAGHEL E A, MARCK B T, PLYMATE S R,
et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants [J].
Clin Cancer Res, 2011,
17(18): 5913-5925., articleTitle=null, refAbstract=null), Reference(id=1330183525946470653, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=PIKE A C, BRZOZOWSKI A M, WALTON J,
et al. Structural insights into the mode of action of a pure antiestrogen [J].
Structure,
9(2): 145-153., articleTitle=null, refAbstract=null), Reference(id=1330183526009385214, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=EDMONDSON S D, YANG B, FALLAN C. Proteolysis targeting chimeras(PROTACs) in ‘beyond rule-of-five’chemical space: recent progress and future challenges [J].
Bioorg Med Chem Lett, 2019,
29(13): 1555-1564., articleTitle=null, refAbstract=null), Reference(id=1330183526072299775, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=TOURE M, CREWS C. Small-molecule PROTACS: new approaches to protein degradation [J].
Angew Chem Int Ed Engl, 2016,
55(6): 1966-1973., articleTitle=null, refAbstract=null), Reference(id=1330183526131020032, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=ROZENGURT E, SOARES H, SINNETT-SMITH J. Suppression of feedback loops mediated by PI3K/mTOR induces multiple overactivation of compensatory pathways:an unintended consequence leading to drug resistance [J].
Mol Cancer Ther, 2014,
13(11): 2477-2488., articleTitle=null, refAbstract=null), Reference(id=1330183527750021379, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=DOGAN S, SHEN R, ANG D C,
et al. Molecular epidemiology of EGFR and KRAS mutations in 3 026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers [J].
Clin Cancer Res, 2012,
18(22): 6169-6177., articleTitle=null, refAbstract=null), Reference(id=1330183527942959364, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=CHURCHER I. Protac-induced protein degradation in drug discovery: breaking the rules or just making new ones? [J].
J Med Chem, 2017,
61(2): 444-452., articleTitle=null, refAbstract=null), Reference(id=1330183528035234053, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=ZENG S X, HUANG W H, ZHENG X L,
et al. Proteolysis targeting chimera(PROTAC) in drug discovery paradigm:recent progress and future challenges [J].
Eur J Med Chem,2020,
210: 112981., articleTitle=null, refAbstract=null), Reference(id=1330183528182034694, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=SUN X Y, GAO H Y, YANG Y Q,
et al. PROTACs: great opportunities for academia and industry [J].
Signal Transduct Target Ther, 2019,
4: 64., articleTitle=null, refAbstract=null), Reference(id=1330183528282697991, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=NEKLESA T, SNYDER L B, WILLARD R R,
et al. ARV-110: an oral androgen receptor PROTAC degrader for prostate cancer [J].
J Clin Oncol, 2019,
37(7): 259., articleTitle=null, refAbstract=null), Reference(id=1330183528354001160, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=LIN H K, WANG L, HU Y C,
et al. Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase [J].
EMBO J,2002,
21: 4037-4048., articleTitle=null, refAbstract=null), Reference(id=1330183528421110025, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=WEN Y, HU M C, MAKINO K,
et al. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway [J].
Cancer Res, 2001,
60(24): 6841-6845., articleTitle=null, refAbstract=null), Reference(id=1330183528530161930, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=CARDOZO C P, MICHAUD C, OST M C,
et al. C-Terminal Hsp-interacting protein slows androgen receptor synthesis and reduces its rate of degradation [J].
Arch Biochem Biophys, 2003,
410(1): 134-140., articleTitle=null, refAbstract=null), Reference(id=1330183528668573963, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=SARKAR S, BRAUTIGAN D L, PARSONS S J,
et al. Androgen receptor degradation by the E3 ligase CHIP modulates mitotic arrest in prostate cancer cells [J].
Oncogene, 2014,
33(1): 26-33., articleTitle=null, refAbstract=null), Reference(id=1330183528744071436, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=LIN H K, HU Y C, LEE D K,
et al. Regulation of androgen receptor signaling by PTEN(phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells [J].
Mol Endocrinol, 2004,
18(10): 2409-2423., articleTitle=null, refAbstract=null), Reference(id=1330183528806985997, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=SMALL E J, BARON A D, FIPPIN L,
et al. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal [J].
J Urol, 1997,
157(4): 1204-1207., articleTitle=null, refAbstract=null), Reference(id=1330183528890872078, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=CLEMENT O O, FREEMAN C M, HARTMANN R W,
et al. Three dimensional pharmacophore modeling of human CYP17 inhibitors. Potential agents for prostate cancer therapy [J].
J Med Chem, 2003,
46(12): 2345-2351., articleTitle=null, refAbstract=null), Reference(id=1330183528978952463, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=HANDRATTA V D, VASAITIS T S, NJAR V C O,
et al. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis,
in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model [J].
J Med Chem,2005,
48(8): 2972-2984., articleTitle=null, refAbstract=null), Reference(id=1330183529067032848, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=NJAR V C O, BRODIE A M H. Discovery and development of galeterone(TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer [J].
J Med Chem, 2015,
58(5):2077-2087., articleTitle=null, refAbstract=null), Reference(id=1330183529146724625, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=KWEGYIR-AFFUL A K, RAMALINGAM S, PURUSHOTTAMACHAR P,
et al. Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts
in vivo [J].
Oncotarget, 2015,
6(29): 27440-27460., articleTitle=null, refAbstract=null), Reference(id=1330183529209639186, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=PURUSHOTTAMACHAR P, GODBOLE A M, GEDIYA L K,
et al. Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer [J].
J Med Chem,2013,
56(12): 4880-4898., articleTitle=null, refAbstract=null), Reference(id=1330183529285136659, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=PURUSHOTTAMACHAR P, KWEGYIR-AFFUL A K, MARTIN M S,
et al. Identification of novel steroidal androgen receptor degrading agents inspired by galeterone 3β-imidazole carbamate [J].
ACS Med Chem Lett, 2016,
7(7): 708-713., articleTitle=null, refAbstract=null), Reference(id=1330183529373217044, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=HWANG D J, YANG J, XU H,
et al. Arylisothiocyanato selective androgen receptor modulators(SARMs) for prostate cancer [J].
Bioorg Med Chem, 2006,
14(19): 6525-6538., articleTitle=null, refAbstract=null), Reference(id=1330183529452908821, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=CHEN J Y, HWANG DJ, CHUNG K,
et al.
In vitro and
in vivo structure-activity relationships of novel androgen receptor ligands with multiple substituents in the B-ring[J].
Endocrinology, 2005,
146(12): 5444-5454., articleTitle=null, refAbstract=null), Reference(id=1330183529524211990, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=GAO W Q, BOHL C E, DALTON J T. Chemistry and structural biology of androgen receptor [J].
Chem Rev,2005,
105(9): 3352-3370., articleTitle=null, refAbstract=null), Reference(id=1330183529679401239, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=PONNUSAMY S, COSS C C, THIYAGARAJAN T,
et al. Novel selective agents for the degradation of androgen receptor variants to treat castration-resistant prostate cancer[J].
Cancer Res, 2017,
77(22): 6282-6298., articleTitle=null, refAbstract=null), Reference(id=1330183529822007576, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=HWANG D J, HE Y L, PONNUSAMY S,
et al. New generation of selective androgen receptor degraders: our initial design, synthesis, and biological evaluation of new compounds with enzalutamide-resistant prostate cancer activity [J].
J Med Chem, 2019,
62(2): 491-511., articleTitle=null, refAbstract=null), Reference(id=1330183529884922137, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=PONNUSAMY S, HE Y L, HWANG D J,
et al. Orally-bioavailable androgen receptor degrader, a potential next-generation therapeutic for enzalutamide-resistant prostate cancer [J].
Clin Cancer Res, 2019,
25(22): 6764-6780., articleTitle=null, refAbstract=null), Reference(id=1330183529947836698, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=HE Y L, HWANG D J, PONNUSAMY S,
et al. Pyrazol-1-yl-propanamides as SARD and pan-antagonists for the treatment of enzalutamide-resistant prostate cancer [J].
J Med Chem, 2020,
63(21): 12642-12665., articleTitle=null, refAbstract=null), Reference(id=1330183530002362651, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=HE Y L, HWANG D J, PONNUSAMY S,
et al. Exploration and biological evaluation of basic heteromonocyclic propanamide derivatives as SARDs for the treatment of enzalutamide-resistant prostate cancer [J].
J Med Chem,2021,
64(15): 11045-11062., articleTitle=null, refAbstract=null), Reference(id=1330183530069471516, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=OHTSU H, XIAO Z Y, ISHIDA J,
et al. Antitumor agents. 217. Curcumin analogues as novel androgen receptor antagonists with potential as anti-prostate cancer agents[J].
J Med Chem, 2002,
45(23): 5037-5042., articleTitle=null, refAbstract=null), Reference(id=1330183530140774685, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[43], rfOrder=42, authorNames=null, journalName=null, refType=null, unstructuredReference=FUJIMOTO N, MIZOKAMI A, HARADA S,
et al. Different expression of androgen receptor coactivators in human prostate [J].
Urology, 2001,
58(2): 289-294., articleTitle=null, refAbstract=null), Reference(id=1330183530224660766, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[44], rfOrder=43, authorNames=null, journalName=null, refType=null, unstructuredReference=WEN S M, TIAN J, NIU Y J,
et al. ASC-J9
®, and not Casodex or Enzalutamide, suppresses prostate cancer stem/progenitor cell invasion via altering the EZH2-STAT3 signals[J].
Cancer Lett, 2016,
376(2): 377-386., articleTitle=null, refAbstract=null), Reference(id=1330183530304352543, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[45], rfOrder=44, authorNames=null, journalName=null, refType=null, unstructuredReference=WU D P, XU J, YU G M,
et al. Expression staus of fatty acid synthase(FAS) but not HER2 is correlated with the differentiation grade and prognosis of esophageal carcinoma[J].
Hepatogastroenterology, 2013,
60(121): 99-106., articleTitle=null, refAbstract=null), Reference(id=1330183530388238624, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[46], rfOrder=45, authorNames=null, journalName=null, refType=null, unstructuredReference=WEN S M, NIU Y J, LEE S O,
et al. Targeting fatty acid synthase with ASC-J9 suppresses proliferation and invasion of prostate cancer cells [J].
Mol Carcinog, 2016,
55(12):2278-2290., articleTitle=null, refAbstract=null), Reference(id=1330183530463736097, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[47], rfOrder=46, authorNames=null, journalName=null, refType=null, unstructuredReference=BRADBURY R H, HALES N J, RABOW A A,
et al. Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer [J].
Bioorg Med Chem Lett, 2011,
21(18): 5442-5445., articleTitle=null, refAbstract=null), Reference(id=1330183530627313954, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[48], rfOrder=47, authorNames=null, journalName=null, refType=null, unstructuredReference=BRADBURY R H, ACTON D G, GRIFFIN N L,
et al. Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer[J].
Bioorg Med Chem Lett, 2013,
23(7): 1945-1948., articleTitle=null, refAbstract=null)], funds=[Fund(id=1330183525057278191, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, awardId=82073684, language=CN, fundingSource=国家自然科学基金(82073684), fundOrder=null, country=null)], companyList=[AuthorCompany(id=1330183521865412817, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, xref=1., ext=[AuthorCompanyExt(id=1330183521873801426, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, companyId=1330183521865412817, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
1.Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203), AuthorCompanyExt(id=1330183521886384339, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, companyId=1330183521865412817, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
1.中国科学院上海药物研究所,上海 201203)]), AuthorCompany(id=1330183523346002133, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, xref=2., ext=[AuthorCompanyExt(id=1330183523371167958, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, companyId=1330183523346002133, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
2.School of Chinese Materia Medic, Nanjing University of Chinese Medicine, Nanjing 210023), AuthorCompanyExt(id=1330183523408916695, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183520594538700, companyId=1330183523346002133, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
2.南京中医药大学,新中药学院,江苏 南京 210023)])], figs=null, attaches=null, journal=Journal(id=1319689822849302687, delFlag=0, nameCn=中国医药工业杂志, nameEn=Chinese Journal of Pharmaceuticals, nameHistory1=null, nameHistory2=null, issn=1001-8255, eissn=null, cn=31-1243/R, coden=ZYGZEA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=etiWDuwx2KO274LHw88KJA==, journalPrice=null, startedYear=null, abbrevIsoEn=Chinese Journal of Pharmaceuticals, journalRemark=null, publicationField=null, createdTime=1792568172420, updatedTime=1792747450744, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=Z, firstLetterEn=Z, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=etiWDuwx2KO274LHw88KJA==, picEn=ip9NF4dK57AmNrCiZ6hmdw==, jcr=null, cjcr=null, exts=[JournalExt(id=1320441770761105589, language=CN, name=中国医药工业杂志, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747450771, updatedTime=1792747450771, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://zgyygyauthor.cast.org.cn/webm, submissionEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionReviewUrl=https://zgyygyauthor.cast.org.cn/webm, submissionCeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionAeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, option={"copyright":""}), JournalExt(id=1320441770819825846, language=EN, name=Chinese Journal of Pharmaceuticals, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747450785, updatedTime=1792747450785, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://zgyygyauthor.cast.org.cn/webm, submissionEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionReviewUrl=https://zgyygyauthor.cast.org.cn/webm, submissionCeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionAeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, option={"copyright":""})], databaseList=null, tenantJournalId=1319690259887390882, websiteList=[Website(id=1319720771623174732, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690259887390882, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgyygy/CN, language=CN, createTime=1792575551181, createBy=18614031015, updateTime=1792746040843, updateBy=18614031015, name=中国医药工业杂志-中文, tplId=1146099689490845704, title=中国医药工业杂志, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428487504769041, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=articleTextType, value=kx, createTime=1792982702375, updateTime=1792982702375, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487475408910, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=banner, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic?fileId=i/3+mr8MqWvs6ArWn9VK7w==, createTime=1792982702368, updateTime=1792982702368, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487538323476, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=grayFlag, value=0, createTime=1792982702383, updateTime=1792982702383, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487462825997, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=logo, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic?fileId=7mfvc3zMp/tsQUIOlJrNFQ==, createTime=1792982702365, updateTime=1792982702365, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487571877910, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=minRunFlag, value=0, createTime=1792982702391, updateTime=1792982702391, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487496380432, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic, createTime=1792982702373, updateTime=1792982702373, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487563489301, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=silenceFlag, value=0, createTime=1792982702389, updateTime=1792982702389, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487483797519, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982702370, updateTime=1792982702370, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487517351954, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=themeColor, value=null, createTime=1792982702378, updateTime=1792982702378, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487525740563, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=themeStyle, value=.style-1 .main-menu ul>li {
margin-right: 18px;
}
@media (max-width: 1442px) {
.style-1 .main-menu ul>li a {
font-size: 16px;
padding: 10px 0;
}
}, createTime=1792982702380, updateTime=1792982702380, creator=18614031015, updator=18614031015)]), Website(id=1319720771702866512, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690259887390882, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgyygy/EN, language=EN, createTime=1792575551200, createBy=18614031015, updateTime=1792746037543, updateBy=18614031015, name=中国医药工业杂志-英文, tplId=1146101810881728533, title=Chinese Journal of Pharmaceuticals, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428509638111261, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=articleTextType, value=kx, createTime=1792982707652, updateTime=1792982707652, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509579391002, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=banner, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic?fileId=i/3+mr8MqWvs6ArWn9VK7w==, createTime=1792982707638, updateTime=1792982707638, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509680054304, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=grayFlag, value=0, createTime=1792982707662, updateTime=1792982707662, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509566808089, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=logo, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic?fileId=7mfvc3zMp/tsQUIOlJrNFQ==, createTime=1792982707635, updateTime=1792982707635, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509701025826, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=minRunFlag, value=0, createTime=1792982707667, updateTime=1792982707667, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509629722652, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic, createTime=1792982707650, updateTime=1792982707650, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509688442913, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=silenceFlag, value=0, createTime=1792982707664, updateTime=1792982707664, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509587779611, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982707640, updateTime=1792982707640, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509663277086, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=themeColor, value=null, createTime=1792982707658, updateTime=1792982707658, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509671665695, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=themeStyle, value=.style-1 .main-menu ul>li {
margin-right: 18px;
}
@media (max-width: 1442px) {
.style-1 .main-menu ul>li a {
font-size: 16px;
padding: 10px 0;
}
}, createTime=1792982707660, updateTime=1792982707660, creator=18614031015, updator=18614031015)])], journalTitle=中国医药工业杂志, weixinUrl=null, journalUrl=http://www.cjph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=Chinese Journal of Pharmaceuticals, journalPhotoCn=etiWDuwx2KO274LHw88KJA==, journalPhotoEn=ip9NF4dK57AmNrCiZ6hmdw==, journalFirstLetter=Z, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/zgyygy/CN/10.16522/j.cnki.cjph.2023.02.001, detailUrlEn=https://castjournals.cast.org.cn/joweb/zgyygy/EN/10.16522/j.cnki.cjph.2023.02.001, pdfUrlCn=https://castjournals.cast.org.cn/joweb/zgyygy/CN/PDF/10.16522/j.cnki.cjph.2023.02.001, pdfUrlEn=https://castjournals.cast.org.cn/joweb/zgyygy/EN/PDF/10.16522/j.cnki.cjph.2023.02.001, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1675958400000, fullTextJson=null, articleText=null, reference=null)